食品和药物管理局批准Niktimvo 慢性移植-反转体-宿主疾病治疗,这是这一疾病的第一个病例。 FDA approves Niktimvo for chronic graft-versus-host disease, a first for this condition.

林业发展局批准了由Incyte和Syndax制药公司研制的9毫克和22毫克小瓶体积的Niktimvo(axatilimab-csfr),作为治疗慢性移植寄生疾病(GVHD)的首例治疗。 The FDA has approved Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vial sizes, developed by Incyte and Syndax Pharmaceuticals, as the first treatment for chronic graft-versus-host disease (GVHD). 它以CSF-1R为目标,减少炎症和纤维化。 It targets CSF-1R to reduce inflammation and fibrosis. 对于已至少尝试过另外两种治疗的40公斤以上的成人和儿科病人,Niktimvo将在2月初得到批准,可以订购。 Approved for adults and pediatric patients over 40 kg who have tried at least two other treatments, Niktimvo will be available for order in early February.